Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
NCT07136714 on ClinicalTrials.gov · last registry update 2026-02-06
Recruiting now, toward 116 participants. Due to report September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change in depressive symptoms. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for psychiatric — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Nordsjaellands Hospital
- Sponsor type
- Other
- Enrollment
- 116
- Started
- 2025-09-11
- Primary completion
- 2027-09 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in depressive symptoms
Conditions studied
Major Depressive Disorder
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.